Editas Medicine is a pioneer in gene editing technology. The biotech holds exclusive rights to CRISPR, a mechanism for cutting and pasting changes to DNA at precise locations.


Updates from The Motley Fool

Latest updates on Editas Medicine from Fool.com.  The Fool has written over 100 articles on Editas Medicine.
Is Editas Medicine a Buy?

There's a long way to go for this biotech. But there could also be a huge payoff if all goes well.



Stock Performance

View Interactive EDIT Charts
Sponsored by

Key Data Points

Primary metrics and data points about Editas Medicine.
Current Price: $26.14
Prev Close: $26.21
Open: $26.32
Bid: $26.20
Ask: $26.54
Day's Range: $25.90 - $26.86
52wk Range: $17.80 - $45.02
Volume: 648,312
Avg Vol 911,162
Market Cap: $1B
P/E (ttm): -9.85
EPS (ttm): -$2.66
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Editas Medicine.
CAPS Rating 5 out of 5
 
233 Outperform
8 Underperform
CAPS All Stars
 
94 Outperform
1 Underperform

How do you think Editas Medicine will perform against the market?



You pick for Editas Medicine is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Katrine Bosley, CEO

100% Approve

Based on 2 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Editas Medicine.

Editas Medicine is a pioneer in gene editing technology. The biotech holds exclusive rights to CRISPR, a mechanism for cutting and pasting changes to DNA at precise locations.

  • Exchange: NASDAQ